Arcus Biosciences Inc (RCUS)
17.10
+0.66
(+3.98%)
USD |
NYSE |
Dec 04, 16:00
17.10
0.00 (0.00%)
After-Hours: 20:00
Arcus Biosciences Revenue (Quarterly): 48.00M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 48.00M |
June 30, 2024 | 39.00M |
March 31, 2024 | 145.00M |
December 31, 2023 | 31.00M |
September 30, 2023 | 32.00M |
June 30, 2023 | 29.00M |
March 31, 2023 | 25.00M |
December 31, 2022 | 34.00M |
September 30, 2022 | 33.00M |
June 30, 2022 | 27.00M |
March 31, 2022 | 18.00M |
December 31, 2021 | 354.62M |
September 30, 2021 | 9.461M |
June 30, 2021 | 9.461M |
March 31, 2021 | 9.461M |
Date | Value |
---|---|
December 31, 2020 | 9.97M |
September 30, 2020 | 64.53M |
June 30, 2020 | 1.75M |
March 31, 2020 | 1.75M |
December 31, 2019 | 9.75M |
September 30, 2019 | 1.75M |
June 30, 2019 | 1.75M |
March 31, 2019 | 1.75M |
December 31, 2018 | 1.562M |
September 30, 2018 | 4.291M |
June 30, 2018 | 1.25M |
March 31, 2018 | 1.25M |
December 31, 2017 | 1.25M |
September 30, 2017 | 0.163M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.75M
Minimum
Mar 2020
354.62M
Maximum
Dec 2021
46.59M
Average
28.00M
Median
Revenue (Quarterly) Benchmarks
Merck & Co Inc | 16.66B |
Regeneron Pharmaceuticals Inc | 3.721B |
NovaBay Pharmaceuticals Inc | 2.441M |
Palatin Technologies Inc | -- |
iBio Inc | -- |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -92.00M |
Total Expenses (Quarterly) | 153.00M |
EPS Diluted (Quarterly) | -1.00 |
Enterprise Value | 462.45M |
Profit Margin (Quarterly) | -191.7% |
Earnings Yield | -18.43% |
Normalized Earnings Yield | -17.07 |